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Abstract
Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically
used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding
efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide,
calcium carbonate, or sevelamer hydrochloride in several experimental models. Lanthanum carbonate and aluminum
hydroxide markedly increased excretion of [32P]-phosphate in feces and reduced excretion in urine in rats with normal
renal function (p < 0.05), indicating good dietary phosphate-binding efficacy. In rats with chronic renal failure, lantha-
num carbonate and aluminum hydroxide reduced urinary phosphate excretion to a greater degree and more rapidly
than calcium carbonate, which in turn was more effective than sevelamer hydrochloride. The potential to induce
adverse pharmacological effects was assessed systematically in mice, rats, and dogs with normal renal function using
standard in vivo models. There was no evidence of any adverse secondary pharmacological effects of lanthanum car-
bonate on the central nervous, cardiovascular, respiratory, or gastrointestinal systems. These studies indicate that
lanthanum carbonate is the more potent of the currently available dietary phosphate binders. No adverse secondary
pharmacological actions were observed in vivo in a systematic evaluation at high doses.
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INTRODUCTION
Hyperphosphatemia is associated with significant mor-
bidity and mortality in patients with chronic kidney dis-
ease,1 and despite treatment, more than half of patients
on dialysis have serum phosphorus levels above Kidney
Disease Outcomes Quality Initiative recommendations
(3.5–5.5 mg/dL).2 Analysis of recent data suggests that
sustained control of serum phosphorus levels within the
range 3.5–5.5 mg/dL can reduce mortality risk in
patients on dialysis,3 indicating a critical need to manage
serum phosphorus levels effectively in these patients.
Restriction of dietary phosphate intake to 800–1000
mg/day is recommended in patients on dialysis whose
serum phosphorus levels exceed 5.5 mg/dL.4 Unfortu-
nately, low-phosphate diets can be unpalatable,5 and
the risk of protein malnutrition may outweigh any ben-
efit of controlling serum phosphorus levels.6 The
administration of dietary phosphate binders is therefore
necessary in most patients on dialysis to effectively
manage their hyperphosphatemia.
Use of aluminum-based phosphate binders was largely
abandoned in the 1980s because of concerns over
accumulation and major toxicities including dialysis
encephalopathy and osteomalacia.7 Calcium-based agents
replaced aluminum but as shown by the theoretical, in
vitro, and healthy volunteer balance studies of Sheikh et al.,
not all calcium-based agents are as effective as alumi-
num.8 The requirement for high daily doses of calcium-
based binders may increase the risk of hypercalcemia,
adynamic bone disease, and vascular calcification.7 The
need for effective treatments with better safety profiles
led to the introduction of the new generation of non-cal-
cium-based phosphate binders, initially sevelamer
hydrochloride9 and then lanthanum carbonate.10
Large comparative clinical studies of lanthanum car-
bonate have generally used a variable dose treat-to-tar-
get design that does not allow direct comparison of
phosphate-binding potency with other binders;11,12
studies have concentrated on differences in the surro-
gate measure of tablet burden.13 However, in vitro
experiments and short-term clinical studies have inves-
tigated the comparative efficacy of lanthanum carbon-
ate and sevelamer hydrochloride.14,15 To our
knowledge, no published studies have directly com-
pared the in vivo efficacy of lanthanum carbonate with
other available phosphate binders in preclinical models.
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Similarly, although the calcium-like pharmacology
of lanthanum in in vitro systems is well known, the
potential of lanthanum carbonate to induce adverse
effects through calcium-like actions has not been evalu-
ated comprehensively in standard in vivo safety-phar-
macology studies.
The aims of the investigations described here were
to directly compare the phosphate-binding efficacy of
lanthanum carbonate with other clinically used phos-
phate binders in vivo and to systematically evaluate any
potential of lanthanum to induce adverse pharmacolog-
ical effects in standard in vivo models.
MATERIALS AND METHODS
Lanthanum carbonate was supplied by Catalytica Phar-
maceuticals Inc. (Greenville, NC, USA), Johnson
Matthey (London, UK), Quintiles Scotland Ltd.
(Edinburgh, UK), or Shire Pharmaceutical Development
Ltd. (Basingstoke, UK). Sevelamer hydrochloride was
supplied by Genzyme BV (Naarden, the Netherlands).
Calcium carbonate and aluminum hydroxide were
supplied by Sigma Chemical Co. (St. Louis, MO,
USA) or Sigma-Aldrich (Poole, UK).
Primary Pharmacology
Rats were supplied by Charles River Laboratories Ltd.
(Margate, UK), Iffa Credo (Brussels, Belgium), or
Harlan Sprague Dawley Inc. (Indianapolis, IN, USA).
Animals were housed individually or in groups and
transferred to individual metabolic cages when
required. Protocols adhered to the ‘Principles of Labo-
ratory Animal Care’ (NIH publication #85-23, revised
in 1985), were approved, and complied with national
laws and guidelines.
Lanthanum carbonate, aluminum hydroxide, and
calcium carbonate were administered by oral gavage in
0.5–2% (w/v) carboxymethyl cellulose (Sigma-Aldrich
Inc., Milwaukee, WI, USA). Sevelamer hydrochloride
was administered in water. All phosphate binders were
administered in a volume of 10–20 mL/kg body weight
per day.
In experiments requiring a state of chronic renal fail-
ure, anesthetized rats underwent 5/6th nephrectomy,
performed in two stages by ligation of two of the three
branches of the left kidney artery, 1 week before com-
plete removal of the right kidney. Animals were allowed
to stabilize postsurgery, before treatments were initiated.
Effect of lanthanum carbonate and aluminum hydroxide on 
excretion of [32P]-phosphate in rats with normal 
renal function
Male Sprague Dawley rats (Crl: CD® BR, n = 5 per
group; ∼8 weeks old; weight range = 100–200 g) received
vehicle, lanthanum carbonate (1000 mg/kg/day), or alu-
minum hydroxide (1000 mg/kg/day) for 12 days. On day
7, a single dose of radiolabeled [32P]-phosphate (11 μCi)
was administered to each animal by oral gavage 30 min
following dosing with phosphate binder. Urine (includ-
ing cage wash) and feces were collected continuously
for 144 h post-[32P]-phosphate dose. Excretion sam-
ples were stored below −20°C before analysis. Fecal
samples were solubilized in Soluene®-350 (Canberra
Packard, Reading, UK) before mixing with Hionic
Fluor scintillant (Canberra Packard), whereas urine
samples were mixed with Ultima Gold scintillant (Can-
berra Packard). Radioactive content was determined in
triplet aliquots, by liquid scintillation counting (Can-
berra Packard). Data are presented as mean cumulative
percentage of administered [32P]-phosphate dose ±
standard deviation (SD). Data were analyzed using a
Kruskal–Wallis test followed by a pairwise Mann–
Whitney test.
Effect of lanthanum carbonate on calcium and phosphate 
metabolism in rats with normal renal function or chronic 
renal failure
Male rats with normal renal function [Crl:
CD®(SD)BR strain VAF plus, n = 10 per group; <6
weeks old; weight range = 141–169 g] were dosed daily
for 13 weeks with vehicle or lanthanum carbonate
(200, 600, or 2000 mg/kg/day). During week 13, blood
samples were taken by retro-orbital sinus puncture
from animals anesthetized under halothane after an
overnight fast. Serum calcium and phosphorus levels
were measured in samples prepared in lithium-heparin
anticoagulant. Parathyroid hormone (PTH) levels were
determined in plasma samples isolated by blood coagu-
lation at room temperature followed by centrifugation
and subsequent plasma precipitation at less than −18°C.
Urinary phosphate concentrations were also determined
in samples collected overnight. Data are presented as
mean ± SD. Data were analyzed by analysis of variance,
followed by pairwise comparison of all treatment groups
versus the vehicle-treated control group using the Will-
iams test. For the comparison of the 2000 mg/kg/day
group versus the control group, a two-sided test was per-
formed (significance at 5% level). If this comparison was
not significant then testing was stopped, otherwise the
process continued (using a one-sided test) with the lower
dose groups until a nonsignificant comparison was
encountered.
In a second study, chronic renal failure was induced
by 5/6th nephrectomy. Male Wistar rats (n = 10 per
group) were treated with vehicle or lanthanum carbon-
ate (100, 500, 1000, or 2000 mg/kg/day) for 12 weeks.
Blood and urine biochemistry were examined. Detailed
methodology is described in Behets et al.16 Data are
presented as mean ± SD. For each time point and
variable, a Kruskal–Wallis test was performed to test
for differences between groups, followed by a Mann–
Whitney  U-test with Bonferroni correction when
significant differences between groups were found.
Differences between groups were considered signifi-
cant at p < 0.05.Pharmacology of Lanthanum Carbonate 219
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Relative urinary phosphate-lowering effect of lanthanum 
carbonate, aluminum hydroxide, calcium carbonate, 
and sevelamer hydrochloride in rats with chronic renal 
failure
Male Sprague Dawley rats (aged ∼12 weeks; weight
range = 280–300 g) underwent 5/6th nephrectomy.
After a 2-week recovery period, animals were dosed
daily for 6 weeks with 1000 mg/kg/day of lanthanum
carbonate, aluminum hydroxide, calcium carbonate,
sevelamer hydrochloride, or vehicle (n = 10 for each
treatment group). Twenty-four-hour urine samples
were collected before surgery and after 0, 2, 4, and 6
weeks of treatment. Urine samples were centrifuged to
remove sediment and aliquots were analyzed colorimet-
rically for phosphate. Data are reported as mean ± SD.
Data were analyzed using a one-way analysis of vari-
ance. The comparison between treatment groups was
made using Dunnett’s procedure with the vehicle-
treated Control group as a reference.
Safety Pharmacology
The safety pharmacology of lanthanum carbonate was
investigated thoroughly in mice, rats, and dogs, with
standard methods applied to identify adverse pharma-
cological effects on the cardiovascular and respiratory
systems, central nervous system (CNS), and gas-
trointestinal (GI) tract. The studies are listed in Table 1,
and the methods employed can be found in publica-
tions by the International Conference on Harmonisation
of Technical Requirements for Registration of Pharma-
ceuticals for Human Use17 and Vogel et al.18 All doses
of lanthanum carbonate refer to the salt and not the
cation.
RESULTS
Primary Pharmacology
Effect of lanthanum carbonate and aluminum hydroxide 
treatment on excretion of [32P]-phosphate in rats with 
normal renal function
The effects of oral administration of lanthanum car-
bonate and aluminum hydroxide on mean urinary and
fecal excretion of [32P]-phosphate are shown in Figure 1.
Following the oral administration of [32P]-phosphate in
vehicle-treated animals, 13.0 ± 2.4% of the adminis-
tered dose was recovered in urine within 144 h. Treat-
ment of rats with lanthanum carbonate (1000 mg/kg/
day) for 6 days before administration of [32P]-phos-
phate resulted in a statistically significant reduction
(82.2%) in recovered radioactivity (i.e., 2.3 ± 2.0% of
the administered dose) compared with vehicle-treated
controls (p < 0.05) (Figure 1A). Lanthanum carbonate
treatment also resulted in a statistically significant
increase (82.1%) in fecal [32P]-phosphate excretion
compared with vehicle-treated controls (55.6 ± 6.6% vs.
30.5 ± 5.9% of the administered dose, respectively, p <
0.05) (Figure 1B). At the same dose (1000 mg/kg/day),
treatment with aluminum hydroxide also resulted in a
marked reduction of mean urinary phosphate excretion
(91.4%, i.e., 1.1 ± 1.3% in the administered dose, p <
0.05), with an increase in fecal [32P]-phosphate excre-
tion (89.7%, i.e., 57.9 ± 14.2% of the administered
dose, p < 0.05). There were no significant differences
in the reduction in urinary [32P]-phosphate excretion
and the increase in fecal [32P]-phosphate excretion
between lanthanum carbonate and aluminum hydrox-
ide groups.
Effect of lanthanum carbonate on calcium and phosphate 
metabolism in rats with normal renal function or chronic 
renal failure
The effect of lanthanum carbonate treatment on serum
and urine biochemistry was investigated in rats with
normal renal function during a 13-week study. The
same parameters were then assessed in a 12-week study
in rats with 5/6th nephrectomy-induced chronic renal
failure.
In rats with normal renal function, lanthanum car-
bonate treatment (200–2000 mg/kg/day) resulted in a
dose-dependent reduction in urinary phosphate excre-
tion. Mean urinary phosphate excretion was signifi-
cantly lower in the 600 mg/kg/day and the 2000 mg/kg/
day lanthanum carbonate groups (6.3 ± 3.3 and 1.4 ±
2.0 mg/16 h, p < 0.01 and p < 0.001, respectively)
compared with vehicle-treated controls (12.1 ± 5.3 mg/
16 h, Figure 2). No significant changes in serum phos-
phorus, PTH, or calcium levels were observed in rats
with increasing doses of lanthanum carbonate. The
urinary calcium concentration was also unaffected by
lanthanum carbonate treatment, except for a small
but significant increase at the highest dose (2000 mg/
kg/day,  p < 0.001 compared with vehicle-treated
controls).
In rats with 5/6th nephrectomy-induced chronic
renal failure (Figure 3), the levels of serum phosphorus
and PTH observed in vehcile-treated control animals
after 12 weeks of treatment were higher than those seen
in animals with normal renal function treated for 13
weeks in the previous study, as expected. Lanthanum
carbonate treatment resulted in dose-dependent but
not significant reductions in mean serum phosphorus
and PTH levels (5.6 ± 3.0 mg/dL and 1.2 ± 1.1 pg/dL,
respectively, at 2000 mg/kg/day), restoring these
parameters to the levels in vehicle-treated rats with nor-
mal renal fun ction (6.3 ± 0.5 mg/dL and 2.4 ± 1.3 pg/dL,
respectively). Lanthanum carbonate treatment caused
a dose-dependent reduction in urinary phosphate
excretion, similar to the effect observed in rats with
normal renal function. Mean urinary phosphate con-
centrations were significantly lower in rats treated with
2000 mg/kg/day lanthanum carbonate (1.1 ± 0.4 mg/24
h,  p < 0.05) compared with vehicle-treated controls
(8.5 ± 5.1 mg/24 h; Figure 3). In rats with chronic renal
failure, treatment with the highest dose of lanthanum220 S.J.P. Damment
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carbonate (2000 mg/kg/day) resulted in a nonsignifi-
cant increase in urinary calcium excretion. This effect
was similar to that observed in rats with normal renal
function.
Relative urinary phosphate-lowering effect of lanthanum 
carbonate, aluminum hydroxide, calcium carbonate, 
and sevelamer hydrochloride in rats with chronic 
renal failure
Before surgical induction of chronic renal failure by
5/6th nephrectomy, mean urinary phosphate excretion
was 7.1 ± 3.3 mg/24 h in control animals. This
increased to 12.8 ± 5.6 mg/24 h at 3 weeks postsurgery
and to 19.3 ± 6.0 mg/24 h by the end of the study
(week 6). At a dose of 1000 mg/kg/day, all of the phos-
phate binders prevented the increase in urinary phos-
phate excretion observed in vehicle-treated animals (for
all groups, p < 0.01 for least-squares mean change from
baseline, compared with the vehicle-treated control
group) (Figure 4). Aluminum hydroxide and lanthanum
carbonate rapidly reduced mean urinary phosphate
Figure 1. The effects of lanthanum carbonate and aluminum hydroxide on urinary (A) and fecal (B) excretion of [32P]-phosphate in rats
with normal renal function. Rats (n = 5 per group) were treated with vehicle, lanthanum carbonate, or aluminum hydroxide by oral gav-
age for 12 days. On day 7, animals received a single oral dose of 11 μCi [32P]-phosphate. Urine and feces were then collected continu-
ously for 144 h and sample radioactivity was determined. Data are mean ± SD. 
Notes: *Denotes p < 0.05 versus lanthanum carbonate and aluminum hydroxide; NS, not significant.
(1000 mg/kg/day)
(1000 mg/kg/day)
Time (h)
(A)
(1000 mg/kg/day)
(1000 mg/kg/day)
Time (h)
(B)
Figure 2. Effect of lanthanum carbonate on phosphate, calcium,
and parathyroid hormone (PTH) in rats with normal renal func-
tion. Rats (n = 10 per group) were dosed daily by oral gavage for
13 weeks with vehicle or lanthanum carbonate. Blood and urine
samples were then collected during fasting conditions and phos-
phorus, calcium, and PTH levels were determined. Data are pre-
sented as mean ± SD.
Note: * and ** Denote p < 0.01 and p < 0.001, respectively, ver-
sus vehicle-treated control group.
Serum calcium (mg/dL)
Serum phosphorus (mg/dL)
Urinary calcium (mg/16 h)
Serum PTH (pg/dL)
**
**
Urinary phosphate (mg/16 h)222 S.J.P. Damment
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excretion and sustained the reduction to the end of the
6-week treatment period (98.3% and 96.7% reduc-
tions, respectively, compared with vehicle-treated con-
trols at week 6). Mean urinary phosphate excretion was
reduced to a lesser degree by calcium carbonate and
sevelamer hydrochloride (71.7% and 40.7% respec-
tively, compared with vehicle-treated controls at week 6).
Safety Pharmacology
No adverse cardiovascular, respiratory, CNS, or GI phar-
macology was identified in the International Conference
on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use17 core
battery of safety-pharmacology studies (Table 1). The
only pharmacological effect of note was an increase in
gastric pH, observed in rats treated orally with lantha-
num carbonate.
DISCUSSION
Primary Pharmacology
In normal rats, lanthanum carbonate reduced the
absorption of orally administered [32P]-phosphate, as
demonstrated by increased fecal excretion and reduced
urinary excretion of radiolabel compared with vehicle-
treated controls. Aluminum hydroxide, which is recog-
nized as the most potent phosphate binder in clinical
use,7 produced similar changes at the same dose. In
rodent chronic renal failure models, the kidneys retain
partial function and, under conditions of reduced phos-
phate availability, reabsorb phosphate from the urine to
maintain serum concentrations.16 Thus, urinary phos-
phate excretion is a sensitive marker of phosphate-
binder efficacy in these models; the greater the amount
of phosphate bound and trapped in the intestinal
lumen, the greater the amount reabsorbed in the kid-
ney, and the smaller the amount excreted in urine.
Data from uremic rats suggest that lanthanum carbon-
ate and aluminum hydroxide are the most efficacious
binders. Trends suggested more rapid and larger
reductions in urinary phosphate excretion compared
with equivalent gravimetric doses of sevelamer hydro-
chloride or calcium carbonate over a 6-week treatment
period.
Serum phosphorus and PTH concentrations were
not altered in normal rats dosed with lanthanum car-
bonate over a 3-month period, as expected, because
homeostatic mechanisms for regulating mineral metab-
olism are intact. Increased renal resorption of phos-
phate and upregulation of 1,25-dihydroxyvitamin D
synthesis were presumably adequate to maintain serum
phosphorus concentrations within the normal range
without the need to effect changes in PTH secretion
and bone turnover.
In 5/6th nephrectomized rats, phosphate metabo-
lism was disrupted and the effects of lanthanum car-
bonate treatment were distinct from those observed
in normal rats. Serum phosphorus and PTH concen-
trations were elevated in the uremic controls com-
pared with normal controls, as residual kidney
function was inadequate to maintain serum phospho-
rus in the normal range. Treatment with lanthanum
carbonate resulted in dose-related reductions in both
of these parameters, towards the levels observed in
animals with normal renal function. Similar effects
have been observed with sevelamer hydrochloride
treatment in rats with various models of chronic
renal failure.19,20
Figure 3. Effect of lanthanum carbonate on phosphate, calcium,
and parathyroid hormone (PTH) in rats with chronic renal fail-
ure. Rats (n = 10 per group) underwent 5/6th nephrectomy and
were administered vehicle or lanthanum carbonate by oral gavage
for 12 weeks. Blood and urine samples were then collected dur-
ing fasting conditions and levels of phosphorus, calcium, and
PTH were determined. Data are presented as mean ± SD.
Note: *Denotes p < 0.05 versus vehicle-treated control group.16
Serum calcium (mg/dL)
Serum phosphorus (mg/dL)
Urinary calcium (mg/16 h)
Serum PTH (pg/dL)
Urinary phosphate (mg/16 h)
Figure 4. Relative urinary phosphate-lowering effect of lantha-
num carbonate, aluminum hydroxide, calcium carbonate, and
sevelamer hydrochloride in rats with chronic renal failure. Rats
(n = 10) underwent 5/6th nephrectomy. Following stabilization
postsurgery, animals were treated with vehicle or 1000 mg/kg/day
of lanthanum carbonate, aluminum hydroxide, calcium carbon-
ate, or sevelamer hydrochloride by oral gavage for 6 weeks. At
weeks −3, 0, 2, 4, and 6, 24-h urine samples were collected and
analyzed for phosphate levels. Data are presented as mean ± SD.
Source: Adapted from Hutchison.7
Note: *Denotes p < 0.01 for least-squares (LS) mean change
from baseline versus vehicle-treated control group.
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Both normal and uremic rats exhibited a small increase
in urine calcium excretion at high doses of lanthanum car-
bonate, without any significant changes in serum calcium
concentration. This has been reported with other phos-
phate binders.19,20 Phosphate in the intestine acts as a
natural calcium binder, and therefore the use of phos-
phate binders can lead to an increase in the amount of
dietary calcium available for absorption.21 It is possible
that the elevated urine calcium excretion is a consequence
of this phenomenon. Alternatively, as lanthanum carbon-
ate administration reduced urinary phosphate excretion
almost to zero at 2000 mg/kg/day, rats may have been in
negative balance at this dose due to over-efficient binding
of phosphate in the intestine. Under these circumstances,
phosphorus (and hence calcium) may have been mobi-
lized from bone to maintain serum phosphorus concen-
trations in the physiologic range.
Safety Pharmacology
In vitro, lanthanum ions have been widely shown to
have both calcium agonist and antagonist actions,
depending on the proteins or cell systems being investi-
gated.22 The extent to which these effects are relevant
to clinical use of lanthanum carbonate is contentious
due to poor GI absorption and extensive protein bind-
ing,23 resulting in very low systemic levels of free lan-
thanum. The in vitro effects of lanthanum may be
explained by its ability to substitute for calcium at
binding sites on extracellular or cell-membrane-bound
proteins.22 Intracellular processes are unaffected as lan-
thanum appears to be unable to enter healthy cells
except by pinocytosis or phagocytosis.22
In our systematic evaluation of safety pharmacology,
no adverse effects were observed on cardiovascular and
respiratory systems in anesthetized instrumented dogs
following direct duodenal instillation of single doses up
to 2000 mg/kg, equivalent to 17× a daily clinical dose of
3000 mg of elemental lanthanum. Similarly, in con-
scious dogs given daily intravenous lanthanum chloride
injections for 28 days, no adverse cardiovascular effects
were observed despite achievement of extreme plasma
lanthanum concentrations. The complete absence of
cardiovascular effects at such high plasma concentra-
tions suggests that circulating lanthanum ions are
unavailable to bind to calcium-binding sites on cardiac
calcium channels and other proteins as observed in
vitro, presumably because of extensive (≥99.9%) bind-
ing to plasma proteins.23
Electron microscopy studies indicate that lanthanum
ions cannot pass through tight junctions in the blood–
brain barrier;24,25 however, two studies in uremic rats
reported significant levels of lanthanum in the brain, rais-
ing concerns about the potential for cognitive effects in
patients.26,27 Both of these studies used high levels of lan-
thanum administered in a powdered diet, a method that
has recently been shown to carry a high risk of tissue con-
tamination when the brain is dissected during autopsy.28
The current investigations do not suggest a potential for
adverse CNS pharmacology or toxicology. Of note, a
neurobehavioral functional observation battery was con-
ducted during long-term toxicity studies in mice and
dogs as part of the preregistration safety evaluation of lan-
thanum carbonate; no adverse CNS pharmacology was
related to treatment at doses of up to 1500 mg/kg/day in
mice and 2000 mg/kg/day in dogs. Clinical use of lantha-
num carbonate has similarly not been associated with
adverse CNS effects and in a controlled study against
standard treatment, no treatment-related changes in cog-
nitive function were observed in patients undergoing dial-
ysis given lanthanum carbonate for 2 years.29
As phosphate binders are administered in high
doses and are not efficiently absorbed, by far the high-
est concentrations reside in the GI tract. Oral doses of
lanthanum carbonate (≤1000 mg/kg) did not induce
gastric damage or exacerbate the gastric damage
induced by aspirin and did not affect fecal output in
rats. Intestinal transit time for a charcoal meal was not
affected in rats given the same doses, although slightly
reduced gastric emptying was inferred by smaller
quantities of charcoal released into the intestine at
1000 mg/kg compared with controls, but not at 500 mg/kg.
The main effect of lanthanum carbonate on GI physi-
ology was an antacid action, with an approximately 2-
unit increase in gastric pH at 1000 mg/kg in rats. This
is analogous to the antacid action of calcium carbon-
ate, with the carbonate ion consuming protons during
its conversion to water and carbon dioxide.30 No
effects on gastric secretion or pepsin activity occurred
(using about 8× a daily clinical dose of 3000 mg ele-
mental lanthanum), suggesting that this effect may
not be relevant to therapeutic doses.
In conclusion, these in vivo studies indicate that lan-
thanum carbonate is one of the most potent of the cur-
rently available phosphate binders. Furthermore, in a
systematic assessment of the safety pharmacology of
lanthanum carbonate at supratherapeutic doses in ani-
mals, no adverse secondary pharmacological actions of
concern for clinical use were identified.
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